Uso de tartarato de brimonidina para resolução de matting telangiectásico: relato de caso
Use of brimonidine tartrate to resolve telangiectatic matting: case report
Brenno Augusto Seabra de Mello Netto; Yasmin de Rezende Beiriz; Américo Carnelli Bonatto; Gustavo Sasso Benso Maciel; Laila Reggiani de Almeida; José Marcelo Corassa
Resumo
Palavras-chave
Abstract
Sclerotherapy is currently the treatment of choice for telangiectasias and reticular veins, with grade 1A recommendation in the European Guideline for sclerotherapy. The most common side effects of this procedure are hyperpigmentation and telangiectatic matting, the second of which provokes great concern because of the esthetic damage and the difficulty of treatment. Matting refers to vessels with a diameter of less than 0.2 mm, which may emerge irregularly or in well-defined areas, especially on the lower limbs. This report presents a case of matting treated with topical Brimonidine Tartrate.
Keywords
References
1 França LH, Tavares V. Insuficiência venosa crônica: uma atualização. J Vasc Bras. 2003;2(4):18-28.
2 Castro e Silva M, Cabral ALS, Barros N Jr, Castro AA, Santos MERC. Diagnóstico e tratamento da doença venosa crônica. J Vasc Bras. 2005;4(3):S185-94.
3 Jia X, Mowatt G, Burr JM, Cassar K, Cook J, Fraser C. Systematic review of foam sclerotherapy for varicose veins. Br J Surg. 2007;94(8):925-36.
4 Yiannakopoulou E. Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins. Pharmacology. 2016;98(1-2):62-9.
5 Kadam P, Lim J, Paver I, Connor DE, Parsi K. Telangiectatic matting is associated with hypersensitivity and a bleeding tendency. Eur J Vasc Endovasc Surg. 2018;55(4):554-9.
6 Goldman MP, Martin DE, Fitzpatrick RE, Ruiz-Esparza J. Pulsed dye laser treatment of telangiectases with and without subtherapeutic sclerotherapy. J Am Acad Dermatol. 1990;23(1):23-30.
7 Sadick NS, Urmacher C. Estrogen and progesterone receptors: their role in postsclerotherapy angiogenesis telangiectatic matting (TM). Dermatol Surg. 1999;25:7.
8 Davis LT, Duffy DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol. 1990;16(4):327-30.
9 Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment. Dermatol Surg. 1995;21(1):19-29, quiz 31-2.
10 Mann MW. Sclerotherapy: it is back and better. Clin Plast Surg. 2011;38(3):475-87, vii.
11 Parlar B, Blazek C, Cazzaniga S, et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. J Eur Acad Dermatol Venereol. 2015;29(3):549-54.
12 Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical a-adrenergic receptor agonist therapy. J Am Acad Dermatol. 2013;69(6, Suppl 1):44-56.
13 Lowe E, Lim S. Paradoxical erythema reaction of long-term topical brimonidine gel for the treatment of facial erythema of rosacea. J Drugs Dermatol. 2016;15(6):763-5. PMid:27272086.
Submitted date:
01/16/2020
Accepted date:
05/01/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email